New hope for mastocytosis sufferers: targeted drug shows promise in symptom control
NCT ID NCT03731260
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 22 times
Summary
This study tests a drug called avapritinib in people with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. The goal is to see if the drug can reduce symptoms like flushing, fatigue, and stomach issues. About 251 adults will take part, and the study compares avapritinib to a placebo over several months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT SYSTEMIC MASTOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno
Salerno, 84131, Italy
-
A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia
Bologna, 40138, Italy
-
Akademiska sjukhuset, Hematologmottagningen/101A
Uppsala, 751 85, Sweden
-
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, 37126, Italy
-
Brigham & Women's Hospital
Boston, Massachusetts, 02115, United States
-
CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée
Toulouse, 31059, France
-
Charité Universitätsmedizin Berlin
Berlin, 10117, Germany
-
Clatterbridge Cancer Centre NHS Foundation Trust
Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Health System (DUHS)
Durham, North Carolina, 27710, United States
-
Erasmus Medical Center
Rotterdam, 3015 GD, Netherlands
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia
Milan, 20122, Italy
-
Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
London, SE1 9RT, United Kingdom
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Hôpital Pitié-Salpêtrière, Service de Dermatologie
Paris, 75013, France
-
Hôpital de la Timone, Service de dermatologie
Marseille, 13385, France
-
Karolinska University Hospital, Hematologimottagningen R51
Stockholm, 141 86, Sweden
-
Klinikum rechts der Isar, Technische Universität München
Munich, 80802, Germany
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Michigan Medicine, University of Michigan
Ann Arbor, Michigan, 48106, United States
-
NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre
Glasgow, G12 OXL, United Kingdom
-
Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter
Odense, DK-5000, Denmark
-
Oslo Universitetssykehus, Rikshospitalet, Department of Hematology
Oslo, 0372, Norway
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
St. Michael's Hospital
Toronto, Ontario, M5B 1W8, Canada
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
-
Uniklinik RWTH Aachen
Aachen, 52074, Germany
-
University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH)
Hamburg, 20246, Germany
-
University Hospital Antwerp
Edegem, 2650, Belgium
-
University Hospital Basel
Basel, 4031, Switzerland
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University Medical Center Groningen (UMCG)
Groningen, 9713 GZ, Netherlands
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7, Canada
-
University of Kansas Hospital
Kansas City, Kansas, 66160, United States
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center
Mainz, 55131, Germany
-
Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie
Lübeck, 23538, Germany
-
Universitätsmedizin Mannheim, III. Medizinische Klinik
Mannheim, 68167, Germany
-
Virginia Commonwealth University Medical Center
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute, Emory University
Atlanta, Georgia, 30322, United States
-
lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo
Toledo, 45071, Spain
Conditions
Explore the condition pages connected to this study.